Status:
UNKNOWN
The Influence of ABCB1、CYP3A4、CYP3A5、POR Genetic Polymorphism and Other Factors on Tacrolimus Blood Concentration
Lead Sponsor:
National Taiwan University Hospital
Conditions:
Kidney Transplantation
Liver Transplantation
Eligibility:
All Genders
20-65 years
Brief Summary
The purpose of the study is to identify factors that may influence tacrolimus (TAC) pharmacokinetics, and the impact of gene polymorphism (ABCB1, CYP3A4, CYP3A5, POR) on pharmacokinetics of TAC in Tai...
Detailed Description
TAC is one of the most important immunosuppressive agents for organ transplantation. In some patients the dose and concentration of TAC are difficult to adjust because of its narrow therapeutic index ...
Eligibility Criteria
Inclusion
- kidney transplants or liver transplants
- 20 - 65 years old
- receiving tacrolimus as immunosuppressive drugs
Exclusion
- Human immunodeficiency virus-positive status
- Retransplantation or multiorgan transplantation
- non-Asian
Key Trial Info
Start Date :
January 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2018
Estimated Enrollment :
440 Patients enrolled
Trial Details
Trial ID
NCT02707822
Start Date
January 1 2016
End Date
December 1 2018
Last Update
March 14 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Taiwan University Hospital
Taipei, Taiwan